FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109791807> ?p ?o ?g. }

• W2109791807 endingPage "e477" @default.
• W2109791807 startingPage "e477" @default.
• W2109791807 abstract "TO THE EDITOR: Therapy with bevacizumab results in high response rates in patients with malignant glioma. However, the mechanisms of action of bevacizumab are poorly understood. Blood-brain barrier reconstitution and vascular normalization have been proposed as phenoma distinct from classical effects of antiangiogenic therapy (ie, induction of hypoxia). Refined magnetic resonance imaging may help to clarify this issue. We, therefore, read with great interest the case report recently presented by Gerstner et al in Journal of Clinical Oncology that described an area of restricted diffusion in a patient with malignant glioma treated with bevacizumab as analyzed by diffusion weighted imaging (DWI). The diffusion-restricted area was biopsied. Histology displayed diffuse tumor progression. Therefore, the authors conclude that diffusion-restricted areas in patients with glioma who are treated with antiangiogenic therapy could represent a special pattern of recurrent tumor. We agree with the authors that diffusion restriction occurs in patients treated with bevacizumab. In our recently published analysis, 18 patients treated with bevacizumab were prospectively analyzed for areas of diffusion restriction on DWI, and apparent diffusion coefficient maps were generated. We found that diffusion-restricted areas accompanied by a corresponding apparent diffusion coefficient decrease occurred in 13 patients (65%). Magnetic resonance imaging–based perfusion analysis performed in two patients showed reduction of regional cerebral blood flow and volume that corresponded with diffusion restriction during treatment with bevacizumab. In one patient, a diffusion-restricted area was biopsied, and histology demonstrated atypical necrosis. Furthermore, immunohistochemistry showed heavy nuclear staining for hypoxia inducible factor-1 . Thus, although we agree that increases in DWI might reflect tumor recurrence where dense cell packing occurs, such as in lymphoma, our analysis suggests that alternative causes for diffusion restriction exist. In our series, DWI restriction was common in patients whose diseases were responding to treatment. The atypical necrosis together with the hypoxia inducible factor-1 induction would be compatible with chronic hypoxia induced by prolonged antiangiogenic therapy. Whether antiangiogenic therapy truely induces hypoxia might be relevant given the therapy-resistant phenotype and diffuse infiltrating growth pattern often observed in gliomas after antiangiogenic therapy, as hypoxia might contribute to both phenoma." @default.
• W2109791807 created "2016-06-24" @default.
• W2109791807 creator A5014445320 @default.
• W2109791807 creator A5040462911 @default.
• W2109791807 creator A5047601964 @default.
• W2109791807 creator A5074321110 @default.
• W2109791807 creator A5076567865 @default.
• W2109791807 date "2010-09-20" @default.
• W2109791807 modified "2023-09-23" @default.
• W2109791807 title "Bevacizumab-Induced Diffusion Restriction in Patients With Glioma: Tumor Progression or Surrogate Marker of Hypoxia?" @default.
• W2109791807 cites W2002727873 @default.
• W2109791807 cites W2054633892 @default.
• W2109791807 cites W2069900390 @default.
• W2109791807 cites W2087987448 @default.
• W2109791807 cites W2121057526 @default.
• W2109791807 cites W2127745545 @default.
• W2109791807 doi "https://doi.org/10.1200/jco.2010.29.2029" @default.
• W2109791807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20585096" @default.
• W2109791807 hasPublicationYear "2010" @default.
• W2109791807 type Work @default.
• W2109791807 sameAs 2109791807 @default.
• W2109791807 citedByCount "19" @default.
• W2109791807 countsByYear W21097918072012 @default.
• W2109791807 countsByYear W21097918072014 @default.
• W2109791807 countsByYear W21097918072015 @default.
• W2109791807 countsByYear W21097918072016 @default.
• W2109791807 countsByYear W21097918072017 @default.
• W2109791807 countsByYear W21097918072019 @default.
• W2109791807 countsByYear W21097918072022 @default.
• W2109791807 crossrefType "journal-article" @default.
• W2109791807 hasAuthorship W2109791807A5014445320 @default.
• W2109791807 hasAuthorship W2109791807A5040462911 @default.
• W2109791807 hasAuthorship W2109791807A5047601964 @default.
• W2109791807 hasAuthorship W2109791807A5074321110 @default.
• W2109791807 hasAuthorship W2109791807A5076567865 @default.
• W2109791807 hasConcept C121608353 @default.
• W2109791807 hasConcept C126322002 @default.
• W2109791807 hasConcept C141341695 @default.
• W2109791807 hasConcept C142724271 @default.
• W2109791807 hasConcept C143998085 @default.
• W2109791807 hasConcept C178790620 @default.
• W2109791807 hasConcept C185592680 @default.
• W2109791807 hasConcept C2776694085 @default.
• W2109791807 hasConcept C2777802072 @default.
• W2109791807 hasConcept C2778227246 @default.
• W2109791807 hasConcept C2779081379 @default.
• W2109791807 hasConcept C2779256057 @default.
• W2109791807 hasConcept C502942594 @default.
• W2109791807 hasConcept C509974204 @default.
• W2109791807 hasConcept C540031477 @default.
• W2109791807 hasConcept C71924100 @default.
• W2109791807 hasConcept C7836513 @default.
• W2109791807 hasConceptScore W2109791807C121608353 @default.
• W2109791807 hasConceptScore W2109791807C126322002 @default.
• W2109791807 hasConceptScore W2109791807C141341695 @default.
• W2109791807 hasConceptScore W2109791807C142724271 @default.
• W2109791807 hasConceptScore W2109791807C143998085 @default.
• W2109791807 hasConceptScore W2109791807C178790620 @default.
• W2109791807 hasConceptScore W2109791807C185592680 @default.
• W2109791807 hasConceptScore W2109791807C2776694085 @default.
• W2109791807 hasConceptScore W2109791807C2777802072 @default.
• W2109791807 hasConceptScore W2109791807C2778227246 @default.
• W2109791807 hasConceptScore W2109791807C2779081379 @default.
• W2109791807 hasConceptScore W2109791807C2779256057 @default.
• W2109791807 hasConceptScore W2109791807C502942594 @default.
• W2109791807 hasConceptScore W2109791807C509974204 @default.
• W2109791807 hasConceptScore W2109791807C540031477 @default.
• W2109791807 hasConceptScore W2109791807C71924100 @default.
• W2109791807 hasConceptScore W2109791807C7836513 @default.
• W2109791807 hasIssue "27" @default.
• W2109791807 hasLocation W21097918071 @default.
• W2109791807 hasLocation W21097918072 @default.
• W2109791807 hasOpenAccess W2109791807 @default.
• W2109791807 hasPrimaryLocation W21097918071 @default.
• W2109791807 hasRelatedWork W1536103630 @default.
• W2109791807 hasRelatedWork W2462822954 @default.
• W2109791807 hasRelatedWork W2789731973 @default.
• W2109791807 hasRelatedWork W2944910448 @default.
• W2109791807 hasRelatedWork W3032348021 @default.
• W2109791807 hasRelatedWork W3100888824 @default.
• W2109791807 hasRelatedWork W3176704123 @default.
• W2109791807 hasRelatedWork W3208778134 @default.
• W2109791807 hasRelatedWork W4293105156 @default.
• W2109791807 hasRelatedWork W2105403929 @default.
• W2109791807 hasVolume "28" @default.
• W2109791807 isParatext "false" @default.
• W2109791807 isRetracted "false" @default.
• W2109791807 magId "2109791807" @default.
• W2109791807 workType "article" @default.